<?xml version='1.0' encoding='utf-8'?>
<document id="27766544"><sentence text="Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir." /><sentence text="Co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) often accelerates the course of HCV-associated liver disease" /><sentence text=" Daclatasvir (DCV) plus asunaprevir (ASV) have been shown to be highly effective for HCV-infected patients with genotype 1b"><entity charOffset="1-12" id="DDI-PubMed.27766544.s3.e0" text="Daclatasvir" /><entity charOffset="14-17" id="DDI-PubMed.27766544.s3.e1" text="DCV" /><entity charOffset="24-35" id="DDI-PubMed.27766544.s3.e2" text="asunaprevir" /><pair ddi="false" e1="DDI-PubMed.27766544.s3.e0" e2="DDI-PubMed.27766544.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27766544.s3.e0" e2="DDI-PubMed.27766544.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27766544.s3.e0" e2="DDI-PubMed.27766544.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27766544.s3.e1" e2="DDI-PubMed.27766544.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27766544.s3.e1" e2="DDI-PubMed.27766544.s3.e2" /></sentence><sentence text=" Three patients co-infected with HIV/HCV genotype 1b were enrolled in this study" /><sentence text=" Prior to initiation of HCV treatment, the variants associated with L31 and Y93 in the non-structural protein 5A (NS5A) region of the HCV genome were confirmed to be absent using a direct sequencing method" /><sentence text=" Taking into consideration the lower risk of drug-drug interaction and the need for immediate treatment, the patients received 60 mg DCV once daily plus 100 mg ASV twice daily for 24 weeks"><entity charOffset="133-143" id="DDI-PubMed.27766544.s6.e0" text="DCV" /></sentence><sentence text=" In one patient, the alanine aminotransferase level was elevated to 228 IU/L at 24 weeks after the start of treatment, but he completed the 24-week treatment course"><entity charOffset="21-28" id="DDI-PubMed.27766544.s7.e0" text="alanine" /></sentence><sentence text=" All three patients achieved sustained viral response, without severe complications (including HIV virological rebound)" /><sentence text=" Thus, in cases where NS5A variants are confirmed to be absent and patients are antiretroviral therapy-naïve, with CD4+ over 500/μL or HIV well controlled by RAL-based cART, DCV plus ASV may represent a good treatment option for HIV and HCV genotype 1b co-infected patients"><entity charOffset="174-180" id="DDI-PubMed.27766544.s9.e0" text="DCV" /></sentence><sentence text="" /></document>